CoChat

Insulin therapy for type 2 diabetes.

Open access

The DOI matches its Crossref record; 64 of the 66 references it cites were found in a registry or an index.

Abstract

A number of landmark randomized clinical trials established that insulin therapy reduces microvascular complications (1,2). In addition, recent follow-up data from the U.K. Prospective Diabetes Study (UKPDS) suggest that early insulin treatment also lowers macrovascular risk in type 2 diabetes (3). Whereas there is consensus on the need for insulin, controversy exists on how to initiate and intensify insulin therapy. The options for the practical implementation of insulin therapy are many. In this presentation, we will give an overview of the evidence on the various insulin regimens commonly used to treat type 2 diabetes. Secondary analyses of the aforementioned landmark trials endeavored to establish a glycemic threshold value below which no complications would occur. The UKPDS found no evidence for such a threshold for A1C, but instead showed that better glycemic control was associated with reduced risks of complications over the whole glycemic range (“the lower the better”) (4). For the management of type 2 diabetes, this resulted in the recommendation to “maintain glycemic levels as close to the nondiabetic range as possible” (5). However, in contrast to the UKPDS, the Kumamoto study observed a threshold, with no exacerbation of microvascular complications in patients with type 2 diabetes whose A1C was <6.5%, suggesting no additional benefit in lowering A1C below this level (2). Moreover, the intensive glycemia treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, targeting A1C <6.0%, was discontinued because of higher mortality in this group compared with the standard therapy group targeting A1C from 7.0 to 7.9% (6). Therefore, the American Diabetes Association (ADA) recommendation of an A1C target <7.0% seems the most balanced compromise at present (7). Another important conclusion of the UKPDS was that the risk reductions in long-term complications were related to the levels of glycemic control …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-s318

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Relationships between mean end point daily insulin dose (A) and the frequency of patient contact (clinical visits and telephone contacts combined) (B) and mean reduction in A1C, and between mean end point daily insulin dose and mean weight gain (C), during nine randomized trials investigating insulin initiation with NPH insulin, insulin detemir, or insulin glargine. Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C). B does not include Holman, since this publication did not specify the number of interim telephone contacts. Two trials (28,35) did not report mean end point daily insulin dose as units per kilogram per day. We calculated the desired figures from the mean end point dose reported as units per day and mean body weight at study end. Three studies (Riddle and the two studies of Yki-Järvinen [27,36,37]) did not report reduction in A1C. We calculated these values from mean baseline and end point A1C levels.
Figure 1 Relationships between mean end point daily insulin dose (A) and the frequency of patient contact (clinical visits and telephone contacts combined) (B) and mean reduction in A1C, and between mean end point daily insulin dose and mean weight gain (C), during nine randomized trials investigating insulin initiation with NPH insulin, insulin detemir, or insulin glargine. Included studies are Bretzel et al. (34), Fritsche et al. (35), Hermansen et al. (28), Holman et al. (32), Philis-Tsimikas et al. (33), Riddle et al. (27), Rosenstock et al. (29), Yki-Järvinen et al. (36), and Yki-Järvinen et al. (37) (A and C). B does not include Holman, since this publication did not specify the number of interim telephone contacts. Two trials (28,35) did not report mean end point daily insulin dose as units per kilogram per day. We calculated the desired figures from the mean end point dose reported as units per day and mean body weight at study end. Three studies (Riddle and the two studies of Yki-Järvinen [27,36,37]) did not report reduction in A1C. We calculated these values from mean baseline and end point A1C levels.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Cited by

See all 181

Metadata

Authors
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H.
Affiliations
Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
Swinnen, Sanne G.
Venue
Diabetes Care
Published
2009-11-01
Volume
32
Issue
suppl_2
Pages
S253-S259
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2131037080
Cited by
181
References
66
Citations by year
2026: 4 · 2025: 11 · 2024: 15 · 2023: 21 · 2022: 19 · 2021: 12 · 2020: 14 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 11 · 2013: 10 · 2012: 10
FWCI
0.83
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • Sanofi
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin therapy, type 2 diabetes, insulin regimens, glycemic control, HbA1c targets, microvascular complications, UKPDS, ACCORD trial, tight glycemic control
MeSH terms
Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Insulin, Quality of Life, Patient Satisfaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin therapy for type 2 diabetes. https://app.cochat.ai/papers/10.2337/dc09-s318
The paper
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009). Insulin therapy for type 2 diabetes. Diabetes Care. https://doi.org/10.2337/dc09-s318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.